1Boot HJ, De Melker HE, Stolk EA, et al. Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine, 2006, 24( 37-39 ): 6288-6299.
2I Cohen JI. Varicella-zoster vaccine virus: evolution in action. Proe Natl Acad Sci USA, 2007, 104(1 ): 7-8.
3Tugwell BD, Lee LE, Gillette H, et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics, 2004, 113 (3 Pt 1 ): 455-459.
4Lopez AS, Guris D, Zimmerman Let al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose. Pediatrics, 2006, 117(6): e1070-1077.
5Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics, 2003, 112(2): e98-103.
6Levine MJ, Ellison MC, Zerbe GO, et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine, 2000, 18(25): 2915-2920.
8Galil K, Fair E, Mountcastle N, et al. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis, 2002, 186 ( 1 ): 102-105.
9Holcomb K, Weinberg JM. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia. J Drugs Dermatol, 2006, 5 (9): 863-866.
10Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med, 2002, 347( 1 ): 26-34.
